News

Press Releases

Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial Officer

October 16, 2020 -
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael Carruthers to the newly created position of Chief Financial Officer (CFO).
Learn More »

Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation

July 8, 2020 -
Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Abby H. Bronson to the newly created position of Vice President, Patient Advocacy and External Innovation. Ms. Bronson will be responsible for leading patient advocacy and building key external relationships with the muscular dystrophy community with the goal of bringing patient insights into drug development.
Learn More »

Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

June 17, 2020 -
Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly created position of Chief Medical Officer. Dr. Gruis will be responsible for leading clinical, medical and regulatory strategy and operations for the drug pipeline, including EDG-5506, the company’s lead product candidate that is being prepared for clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD).
Learn More »

Edgewise Therapeutics Closes $50 Million Series B Financing

September 17, 2019 -
Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has announced the closing of a $50 million Series B financing round. The round was co-led by Novo Holdings A/S and U.S. Venture Partners (USVP) and included participation from Deerfield Management, New Leaf Venture Partners, and Cure Duchenne Ventures, as well as existing founding investor OrbiMed Advisors. The financing will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. Joining the Board of Directors will be Kenneth Harrison, Ph.D., Principal at Novo Ventures and Jonathan Root, M.D., General Partner at USVP; Robert Jackson, M.D., Partner and CSO at Deerfield will join as a Board Observer.
Learn More »

Upcoming Events

There are no upcoming events.

Past Events

PPMD Annual Conference 2020: “Muscle Health and Exercise”

Date: July 8, 2020

Edgewise is proud to list our investors

Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $13 billion across public and private company investments worldwide.

Our mission is to be a supportive owner of the Novo Group companies and to make a growing and positive impact on health, science and society by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

USVP healthcare team has a unique competence in investing in medical devices, biotechnology and healthcare information technology sectors, with a focus on therapeutic medical devices that enable new or less invasive procedures, molecularly targeted protein or small molecule therapeutics, and information technology-enabled healthcare services, which improve the quality of care and/or significantly reduce costs.

We work with experienced management teams that have developed novel product programs and platforms exemplified by several key characteristics – including large unmet medical needs, strong science, well differentiated technologies, and high-quality pre-clinical and clinical development programs.

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

As of 2018, CureDuchenne’s portfolio includes 16 wide-ranging projects with 4 successful exits. Investments from CureDuchenne Ventures have successfully leveraged more than $1.3 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies to fund emerging projects to find treatments for Duchenne.